Stereotaxis Inc.

STXS Healthcare Medical Instruments & Supplies

Stereotaxis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.4 million, up 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 12.8%, EPS was flat and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.01 0.04 −3.81%
Market cap
$105.2M
P/E
0.0×
Fwd P/E
−8.9×
Dividend yield
—
F-score
5/9
Altman Z
−12.40
Beneish M
−1.95
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 5 5 3

+8 more TTM periods

ROE
(344.36%) (266.26%) (234.28%) (291.61%)
ROA
(48.76%) (46.02%) (46.30%) (51.60%)
ROIC
(203.58%) (278.05%) (260.75%) (1,464.62%)
Return on Tangible Assets
(167.63%) (144.36%) (157.94%) (263.57%)
Average Days of Receivables
168.31 112.54 114.57 64.73
Free Cash Flow per Share
(0.15) (0.16) (0.15) (0.09)
Free Cash Flow
(15.50) (15.52) (13.78) (8.48)
Other line items

Show all line items

Columns are period end dates